Published in Clin Exp Nephrol on January 05, 2008
The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol (2010) 1.46
Hyperbaric oxygen therapy in a patient with autosomal dominant polycystic kidney disease with a perinephritic abscess. Clin Exp Nephrol (2010) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med (1967) 16.75
Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol (1990) 8.97
Oxidative stress: oxidants and antioxidants. Exp Physiol (1997) 6.12
A simple method for clinical assay of superoxide dismutase. Clin Chem (1988) 5.66
Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest (2005) 5.53
Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol (2006) 2.84
Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int (2005) 2.78
Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant (2003) 2.10
The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis (2006) 2.01
Role of hypoxia in the pathogenesis of renal disease. Kidney Int Suppl (2005) 1.57
Effects of hyperbaric oxygen treatment on liver functions, oxidative status and histology in septic rats. Intensive Care Med (2005) 1.48
Free radical formation by antitumor quinones. Free Radic Biol Med (1989) 1.44
Human kidney proximal tubules are the main source of plasma glutathione peroxidase. Am J Physiol (1994) 1.43
Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol (2004) 1.29
Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem (1997) 1.24
Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int (1986) 1.18
Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest (1988) 1.17
Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol (1990) 1.16
Intrarenal oxygen in diabetes and a possible link to diabetic nephropathy. Clin Exp Pharmacol Physiol (2006) 1.11
The involvement of oxidative stress in the progression of renal injury. Blood Purif (1999) 1.07
Multiple effects of hyperbaric oxygen on the expression of HIF-1 alpha and apoptotic genes in a global ischemia-hypotension rat model. Exp Neurol (2005) 0.99
Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study. Nephrol Dial Transplant (2003) 0.98
Oxygen radicals and renal diseases. Miner Electrolyte Metab (1997) 0.97
Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol (1996) 0.95
Endothelial dysfunction: clinical strategies for treating oxidant stress. Am Heart J (2003) 0.94
Effects of statins on oxidative stress. Biol Trace Elem Res (2004) 0.92
The effects of hyperbaric oxygen treatment on oxidant and antioxidants levels during liver regeneration in rats. Tohoku J Exp Med (2004) 0.89
Long-term prognosis and prognostic indices of IgA nephropathy in juvenile and in adult Japanese. Clin Nephrol (1987) 0.85
Suppressive effect of superoxide dismutase on adriamycin nephropathy. Nephron (1992) 0.82
Plasma glutathione peroxidase and its relationship to renal proximal tubule function. Mol Genet Metab (1998) 0.82
Statins prevent dextrose-induced endothelial barrier dysfunction, possibly through inhibition of superoxide formation. Diabetes (2006) 0.80
Selenium in health and disease: a review. Crit Rev Food Sci Nutr (1997) 0.80
The size of the juxtaglomerular apparatus in diabetic glomerulosclerosis and its correlation with arteriolosclerosis and arterial hypertension: a morphometric light microscopic study on human renal biopsies. Clin Nephrol (1977) 0.80
Alpha tocopherol improves focal glomerulosclerosis in rats with adriamycin-induced progressive renal failure. Nephron (1994) 0.80
Adriamycin affects glomerular renal function: evidence for the involvement of oxygen radicals. Free Radic Res Commun (1989) 0.79
Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus-based regimens. Am J Nephrol (2005) 0.78
Hyperbaric oxygen treatment augments the efficacy of a losartan regime in an experimental nephrotic syndrome model. Nephron Exp Nephrol (2006) 0.78
The heat is on: an expanding role for hypoxia-inducible factors in kidney transplantation. J Am Soc Nephrol (2006) 0.75
The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis (2006) 2.01
Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant (2007) 1.91
FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int (2010) 1.81
Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. Pharmacol Res (2005) 1.79
Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol (2011) 1.77
The accuracy of home glucose meters in hypoglycemia. Diabetes Technol Ther (2010) 1.68
Clinical findings in the renal victims of a catastrophic disaster: the Marmara earthquake. Nephrol Dial Transplant (2002) 1.60
Prostate cancer and adiponectin. Urology (2005) 1.59
Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab (2014) 1.57
Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis (2011) 1.55
Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan. Blood Purif (2007) 1.51
Effects of hyperbaric oxygen treatment on liver functions, oxidative status and histology in septic rats. Intensive Care Med (2005) 1.48
Plasma apelin and asymmetric dimethylarginine levels in type 2 diabetic patients with diabetic retinopathy. Diabetes Res Clin Pract (2009) 1.40
Timing of replacement therapy for acute renal failure after cardiac surgery. J Card Surg (2004) 1.33
Melatonin and the ovary: physiological and pathophysiological implications. Fertil Steril (2008) 1.29
Improvement in nutritional parameters after initiation of chronic hemodialysis. Am J Kidney Dis (2002) 1.26
Uremic malnutrition is a predictor of death independent of inflammatory status. Kidney Int (2004) 1.25
Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol (2008) 1.22
Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract (2006) 1.21
Functional roles of melatonin in plants, and perspectives in nutritional and agricultural science. J Exp Bot (2011) 1.19
Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol (2009) 1.13
Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.10
Molecular targets against mustard toxicity: implication of cell surface receptors, peroxynitrite production, and PARP activation. Arch Toxicol (2006) 1.10
Phytomelatonin: a review. J Exp Bot (2008) 1.09
Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol (2012) 1.09
Nonadherence with diet and fluid restrictions and perceived social support in patients receiving hemodialysis. J Nurs Scholarsh (2007) 1.08
Melatonin alleviates lung damage induced by the chemical warfare agent nitrogen mustard. Toxicol Lett (2007) 1.08
ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol (2008) 1.08
Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol (2010) 1.07
Re. Elderly women: homocysteine reduction by short-term folic acid supplementation resulting in increased glucose concentrations and affecting lipid metabolism (C677T MTHFR polymorphism). Nutrition (2013) 1.07
Re. Low folate and vitamin B12 nourishment is common in Omani children with newly diagnosed autism. Nutrition (2013) 1.07
Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin J Am Soc Nephrol (2009) 1.06
Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Crit Rev Oncog (2007) 1.05
Red cell distribution width is independently related to endothelial dysfunction in patients with chronic kidney disease. Am J Med Sci (2014) 1.05
Lung toxicity of nitrogen mustard may be mediated by nitric oxide and peroxynitrite in rats. Res Vet Sci (2006) 1.03
Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med (2008) 1.03
Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant (2008) 1.03
Role of melatonin in metabolic regulation. Rev Endocr Metab Disord (2009) 1.03
Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) (2007) 1.01
Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. Nephrol Dial Transplant (2011) 1.00
The changing biological roles of melatonin during evolution: from an antioxidant to signals of darkness, sexual selection and fitness. Biol Rev Camb Philos Soc (2009) 0.99
Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol (2007) 0.98